ArticleTherapeutic innovation & regulatory science2020
Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials?
Article in Therapeutic innovation & regulatory science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A scoping review of artificial intelligence applications in clinical trial risk assessment.NPJ digital medicine · 2025Article
- Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Role of Quality Assurance in Clinical Trials: Safeguarding Data Integrity and Compliance.Cureus · 2024Review
- Assessment of the Relationship Between Protocol Adherence, Study Complexity and Personnel in Surgical Clinical Trials.Therapeutic innovation & regulatory science · 2023Article
- Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing.Therapeutic innovation & regulatory science · 2022Article
- Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development.Therapeutic innovation & regulatory science · 2021Review
- Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group.CPT: pharmacometrics & systems pharmacology · 2021Article
- Letter to the Editor: New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19.Therapeutic innovation & regulatory science · 2021Article
- Using Statistical Modeling for Enhanced and Flexible Pharmacovigilance Audit Risk Assessment and Planning.Therapeutic innovation & regulatory science · 2021Article
- Leveraging analytics to assure quality during the Covid-19 pandemic - The COVACTA clinical study example.Contemporary clinical trials communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing number of clinical trials and their complexity make it challenging to detect and identify clinical quality issues timely. Despite extensive sponsor audit programs and monitoring activities, issues related to data integrity, safety, sponsor oversight and patient consent have recurring audit and inspection findings. Recent developments in data management and IT systems allow statistical modeling to provide insights to clinical Quality Assurance (QA) professionals to help mitigate some of the key clinical quality issues more holistically and efficiently.
methodsWe used findings from a curated data set from Roche/Genentech operational and quality assurance study data, covering a span of 8 years (2011-2018) and grouped them into 5 clinical impact factor categories, for which we modeled the risk with a logistic regression using hand crafted features.
resultsWe were able to train 5 interpretable, cross-validated models with several distinguished risk factors, many of which confirmed field observations of our quality professionals. Our models were able to reliably predict a decrease in risk by 12-44%, with 2-8 coefficients each, despite a low signal-to-noise ratio in our data set.
conclusionWe proposed a modeling strategy that could provide insights to clinical QA professionals to help them mitigate key clinical quality issues (e.g., safety, consent, data integrity) in a more sustained data-driven way, thus turning the traditional reactive approach to a more proactive monitoring and alerting approach. Also, we are calling for cross-sponsors collaborations and data sharing to improve and further validate the use of statistical models in clinical QA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.